Raqualia Pharma Inc.

Toray Industries, Inc.

Kaoru Shimada

Hiroshi Takahashi

Nobuyuki Takahashi

Masaki Sudo

Yasuhiro Iwata

Naotoshi Tomita

Kiyoshi Kawamura

Tatsuya Yamagishi

Mikio Morita

Shinichi Koizumi

Tadashi Inoue

Yoshimasa Arano

Shuzo Watanabe

Yoshiyuki Ueno

Yoshiyuki Okumura

Hirohide Noguchi

Hiroaki Wakabayashi

Masato Masuda

Masaomi Tajimi

Keiko Obata

Makiko Kuroda

Toyoharu Numata

Megumi Nakanishi

Kazuhiko Nonomura

Shungo Kanda

Hirofumi Yamanaka

Toshinori Yamamoto

Mayumi Kashino

Hiromitsu Yoshida

Shunsuke Komachi

The present invention aims to provide a material for adsorbing soluble tumor necrosis factor receptors with high efficiency. The present invention provides an adsorbing material for soluble tumor necrosis factor receptors, which includes a superficially porous water-insoluble polymeric material, wherein the pore size distribution curve for the surface of the water-insoluble polymeric material, which is derived from a distribution of melting points determined by differential scanning calorimeter, shows the peak radius in the range of 1 to 80 nm, and the water-insoluble polymeric material has a zeta potential at pH 7.4 of −15 to 15 mV, and the water-insoluble polymeric material is in fiber, particle, or film form.

Adsorbing material for soluble tumor necrosis factor receptor

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Material for removing activated leukocyte-activated platelet complex

An object of the present invention is to provide a carrier for adsorbing organic matter, which achieves both of adsorption ability for organic matter and suppression of pressure increase. The present invention provides a carrier for adsorbing organic matter, comprising a sea-island type solid composite fiber, wherein the pore volume is 0.05 to 0.5 cm/g and the fiber diameter is 25 to 60 &#x3bc;m.

Carrier for adsorbing organic matter

The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.

Ghrelin receptor agonist for treatment of cachexia

An adsorption carrier-packed column includes a central pipe, adsorption carrier, plate A, and plate B, wherein an insertion material C is inserted between the adsorption carrier and the plate A; an insertion material D is inserted between the adsorption carrier and the plate B; the ratio of the deformation rate of the insertion material C (C) to the deformation rate of the adsorption carrier (E) is 1&#x3c;C/E&#x3c;10, and the ratio of the deformation rate of the insertion material D (D) to the deformation rate of the adsorption carrier (E) is 1&#x3c;D/E&#x3c;10; and the ratio of the thickness of the insertion material C (T) to the distance of a gap between the adsorption carrier and the plate A (L) is 1.1&#x3c;T/L&#x3c;4, and the ratio of the thickness of the insertion material D (T) to the distance of a gap between the adsorption carrier and the plate B (L) is 1.1&#x3c;T/L&#x3c;4.

Adsorption carrier-packed column

The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor. 

Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor. 

Serine derivatives as ghrelin receptor agonists

This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.

5-HT4 receptor agonist for gastroparesis

The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blocker such as Naand Na, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved. 

Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

The present invention relates to novel crystal forms of 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate. More particularly, the invention relates to polymorph forms, and to processes for the preparation of compositions containing and to uses of such polymorph forms.

Polymorph forms

The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.

Pharmaceutical composition

The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Naand Na, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved. 

Growing community of inventors

Aichi, Japan

Kaoru Shimada